Antengene Announces One Oral and Three Poster Presentations at ASCO 2024

USA - English

• APAC - English

• Oral session：ATG-008 (mTORC1/2 Inhibitor) combined with PD-1 antibody in Phase II studies for cervical cancer
• Three Poster presentations: Phase I/II studies for ATG-031 (anti-CD24 monoclonal antibody) and ATG-022 (Claudin 18.2 antibody-drug conjugate) and selinexor (XPO1 Inhibitor)

SHANGHAI and HONG KONG, April 25, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for cancer, today announced the presentation of four abstracts (including one oral presentation and three poster presentations) at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place from May 31^st to June 4^th at the McCormick Place Convention Center in Chicago, IL, the United States.

Details of the Oral Presentation:

ATG-008 (mTORC1/2 Inhibitor)
Title: A phase I/II study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort
Abstract: 5509
Session: Clinical Science Symposium – Stronger Together: Novel Combinations Across the Gynecologic Cancer Spectrum
Date: June 1, 2024
Time: 1:15 PM - 2:45 PM (Central Daylight Time)
           2:15 AM - 3:45 AM, June 2, 2024 (Beijing Time)

Details of the Poster Presentations:

ATG-031 (anti-CD24 monoclonal antibody)
Title: A first-in-human phase I study of ATG-031, anti-CD24 antibody, in patients with advanced solid tumors or B-cell non-Hodgkin lymphomas (PERFORM)
Abstract: TPS2691
Session: Developmental Therapeutics—Immunotherapy
Date: June 1, 2024
Time: 9:00 AM - 12:00 PM (Central Daylight Time)
          10:00 PM, June 1 - 1:00 AM, June 2, 2024 (Beijing Time)

ATG-022 (Claudin 18.2 Antibody-drug Conjugate)
Title: An open-label, multicenter, phase I study of ATG-022 in patients with advanced/metastatic solid tumors (CLINCH)
Abstract: 3032
Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Date: June 1, 2024
Time: 9:00 AM - 12:00 PM (Central Daylight Time)
          10:00 PM, June 1 - 1:00 AM, June 2, 2024 (Beijing Time)

Selinexor (XPO1 Inhibitor) 
Title: Selinexor combined with tislelizumab in patients with relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL): Results of dose escalation of cohort C, from a multicenter, single-arm, phase I/II study (TOUCH)
Abstract: 7065
Session: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Date: June 3, 2024
Time: 9:00 AM - 12:00 PM (Central Daylight Time)
          10:00 PM, June 3 - 1:00 AM, June 4, 2024 (Beijing Time)

About Antengene

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a leading commercial-stage R&D-driven global biopharmaceutical company focused on the discovery, development, manufacturing and commercialization of innovative first-in-class/best-in-class therapeutics for the treatment of hematologic malignancies and solid tumors, in realizing its vision of "Treating Patients Beyond Borders".

Since 2017, Antengene has built a pipeline of 9 oncology assets at various stages going from clinical to commercial, including 6 with global rights, and 3 with rights for the APAC region. To date, Antengene has obtained 29 investigational new drug (IND) approvals in the U.S. and Asia, and submitted 10 new drug applications (NDAs) in multiple Asia Pacific markets, with the NDA for XPOVIO^® (selinexor) already approved in Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2023, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

Investor Contacts: 
Donald Lung
E-mail: [email protected]
Mobile: +86 18420672158

PR Contacts:
Peter Qian
E-mail: [email protected]
Mobile: +86 13062747000

SOURCE Antengene Corporation Limited